Laser Eye Surgery

... PRESS RELEASE NicOx compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration Home Printer-Friendly NicOx compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration Sophia Antipolis Cedex - (MARKET WIRE) - 03/02/2006 - March 2, 2006.

Sophia Antipolis, France.

www.nicox.com NicOx S.A.

(Eurolist: NICOX) today announced that it has achieved very promising pre-clinical results in its collaboration with Pfizer Inc.

(NYSE: PFE), which is focused on the development of more effective treatments for glaucoma using NicOx' proprietary nitric oxide-donating technology.

The NicOx compound proved to be significantly more effective than the reference drug in a validated in vivo model of abnormally high intraocular pressure (IOP, pressure within the eye) and was superior to the reference drug in two other validated models.

NicOx also announced today that it has signed a major new agreement which grants Pfizer exclusive rights to use its technology across the entire field of ophthalmology (see separate press release).

It is estimated that over 3 million people in the United States suffer from glaucoma and 120,000 are believed to have lost their vision as a result of the disease (see NOTE 1).

Current drug therapy is focused on reducing IOP, which is believed to cause progressive vision impairment.

The degree of I...

Read more...